All In Biotech

Drug Trial Radar · NCT05155839

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

An Open-label, Multicenter, First-in-human, Phase I Dose-escalation and Expansion Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of MRG001 in Patients With CD20-positive Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Last checked: Nov 20, 2026Latest source record: Feb 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

108

Planned (sponsor's estimate)

Start

Jun 25, 2019

Primary completion

Oct 2022

Study completion Oct 2023

Sponsor

Lead sponsor
Shanghai Miracogen Inc.Industry
Sponsor type
Industry
First posted
Dec 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of two parts. Phase Ia is a dose escalation study to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG001. Phase Ib is a dose expansion study to assess the preliminary efficacy of MRG001 in patients with CD20-positive relapsed or refractory B-cell NHL at the confirmed RP2D. The safety, tolerability, pharmacokinetic (PK) and immunogenicity of MRG001 will be evaluated in both parts.

Conditions

  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Interventions

  • MRG001Drug

    Administrated intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: Baseline to 90 days after the last dose of study treatment.
  2. Maximum Tolerated Dose (MTD)Time frame: DLT will be evaluated during the first treatment cycle (Day 1-21).
  3. Recommended Phase II Dose (RP2D)Time frame: Baseline to study completion (up to 15 months).

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Cancer Hospital & Institute

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat-sen University Cancer Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Harbin First Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.